<DOC>
	<DOCNO>NCT00274261</DOCNO>
	<brief_summary>This multicenter , randomize , double-masked , control , phase III study repeat use C31G vaginal gel compare Conceptrol® Vaginal Gel primary method contraception six month ( 183 day ) least six cycle use . In addition , opportunity subject continue study treatment twelve month ( 365 day ) twelve cycle treatment upon completion first six month treatment .</brief_summary>
	<brief_title>Study Safety Contraceptive Efficacy C31G Compared Conceptrol®</brief_title>
	<detailed_description>Approximately 85 % American woman ( 52 million ) age 15 44 sexually active . Approximately two-thirds 38 million woman use form birth control and/or STD prevention . With grow awareness risk STDs , increase number woman require contraceptive method provide protection STDs addition provide basic contraceptive function . Currently single , reasonably effective method achieve end . Condoms , male female , present problem acceptability partner many at-risk woman , thus , consider effective contraceptive STD preventive many people . A spermicide also ability prevent transmission STDs would major advance , tremendous value woman worldwide . C31G effective spermicide vitro activity equal N-9 . C31G find broad-spectrum antibacterial agent vitro animal , active gram-positive gram-negative organism , include chlamydia , range antibiotic resistant strain . It also active envelop virus include HIV HSV . Thus , primary objective study determine contraceptive efficacy C31G vaginal gel compare Conceptrol® Vaginal Gel . The secondary objective determine safety acceptability compound use period six month twelve month . Additional evaluation include incidence urinary tract infection ( UTI ) , bacterial vaginosis ( BV ) yeast vaginitis follow use C31G vaginal gel compare Conceptrol® Vaginal Gel .</detailed_description>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Nonoxynol</mesh_term>
	<criteria>Potential subject must : Be healthy woman , sexually active , risk pregnancy desire contraception . Be within age range 18 40 year inclusive . Be lowrisk human immunodeficiency virus ( HIV ) sexually transmit disease ( STD ) infection currently single sex partner ( minimum 4 month ) also lowrisk HIV STD . Have negative urine pregnancy test prior enrollment . Have normal cyclic menses usual length 24 35 day last 2 cycle least one spontaneous , normal menstrual cycle ( 2 menses ) since delivery , abortion , discontinue hormonal contraception/hormonal therapy . Be willing accept risk pregnancy . Be willing engage least 4 act heterosexual vaginal intercourse per month period 6 month . Be willing randomize either study treatment . Be willing use study product primary method contraception course study exception emergency contraception ( EC ) , indicate . Be capable use study product properly agree observe study direction requirement . Be willing keep diary record coital information , product use information , information use vaginal product , sign symptom data subject partner . Agree participate clinical trial course study . Be willing give write informed consent participate trial . Potential subject must : Have history allergy sensitivity spermicide product contain N9 . Have 3 urinary tract infection ( UTI ) past year . Have UTI urine culture symptomatic yeast vaginitis symptomatic bacterial vaginosis diagnose wet mount unless treat proof cure document . Be pregnant , suspected pregnancy desire become pregnant course study . Have history infertility condition may lead infertility , without subsequent intrauterine pregnancy . Have contraindication pregnancy ( medical condition ) chronic use category D X medication . Have one sexual partner last 4 month . Have share injection drug needle within past 12 month . Have suspect HIV infection . Have diagnose genital herpes simplex virus ( HSV ) , first occurrence ( initial episode ) within three month prior screen . Have 3 outbreak HSV within last year . Have diagnose STDs ( include trichomonas ) 6 month prior screen visit ( exception Human Papilloma Virus [ HPV ] ) . Be lactate breastfeed . Have clinically significant abnormal vaginal bleeding spot within month prior screen . Have clinically significant abnormal find pelvic examination baseline lab , view investigator , precludes participate trial . Have clinically significant sign vaginal cervical irritation pelvic examination . Have vaginal cervical biopsy vaginal surgery within 3 month prior screen . Have use vaginal systemic antibiotic antifungal within 14 day prior screen randomization . Have DepoProvera® injection 10 month prior enrollment . Have abnormal Pap smear high grade squamous intraepithelial lesion ( HSIL ) , atypical glandular cell ( AGC ) ASCH ( atypical squamous cell , exclude HSIL ) within last 12 month . Have abnormal Pap smear lowgrade squamous intraepithelial lesion ( LSIL ) ASCUSHPV HR positive unless resolve colposcopy . Have Cervical Intraepithelial Neoplasia ( CIN ) diagnosis biopsy within last 12 month . Have history current diagnosis cervical cancer . Consume ( average ) great three drink alcoholic beverage per day . Have past history ( within twelve month ) current history drug abuse [ recreational , prescription overthecounter ( OTC ) ] . Have take investigational drug use investigational device within past 30 day . Have previously participate complete study phase III study C31G . Have issue concern ( judgment investigator ) may compromise safety subject confound reliability compliance information acquire study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>contraception</keyword>
</DOC>